Switching from warfarin to direct-acting oral anticoagulants: it is
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward! . Authors Mahmoud Abdelnabi 1 2 , Juthipong Benjanuwattra 3 , Osama Okasha 4 , Abdallah Almaghraby 5 , Yehia Saleh 6 , Fady Gerges 7 Affiliations
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical
ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con - ditions.
An update on applications and limitations of direct oral anticoagulants
The widely used oral anticoagulants include warfarin, phenprocoumon, acenocoumarol which acts as a vitamin K antagonist, dabigatran, a thrombin inhibitor, and factor Xa inhibitor including apixaban, edoxaban, and rivaroxaban and commonly used parenteral anticoagulants include heparin, thrombin inhibitors (bivalirudin, argatroban) and fondaparinux
Frontiers | Direct Oral Anticoagulants: From Randomized Clinical Trials
The introduction of direct oral anticoagulants (DOACs) has induced a thorough frameshift in the primary and secondary prevention of ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) as well as in prevention and treatment of venous thromboembolism (VTE), namely, pulmonary embolism and deep venous thrombosis ( Chan et al.,
- What are direct oral anticoagulants?
- Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for prevention and treatment of several cardiovascular conditions.
- What are direct oral anticoagulants (DOACs)?
- 3 Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland OR. Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist.
- Which anticoagulants are used in Egyptian medicine?
- The Egyptian Journal of Internal Medicine 35, Article number: 26 (2023) Cite this article A major advancement in the field of medicine has been the introduction and usage of direct oral anticoagulants (DOACs) such as dabigatran (Pradaxa), apixaban (Eliquis), and rivaroxaban (Xarelto).
- Are direct oral anticoagulants a good alternative to vitamin K antagonist?
- ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long- standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con-ditions.
- Can direct oral anticoagulants prevent stroke in AF?
- In recent years, four direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban and edoxaban, have been compared with warfarin for stroke prevention in AF, in large, phase 3, randomised, controlled trials (RCTs).
- How effective are DOACs for venous thromboembolism?
- DOACs have been found to be at least as safe and effective as vitamin K antagonists in randomised, controlled trials for stroke prevention in AF and the management of venous thromboembolism, with real-world data showing similar outcomes. With the availability of several agents, selecting the most appropriate DOAC can be challenging.
